Skip to main content
Year archive

Zelluna ASA — 2020 filings

All 55 regulatory filings released by Zelluna ASA (ULTI) in 2020, sourced directly from the official regulator.

55 Filings
2020 Period
2020 filings (55)
Filing Released Lang
Shareholder Notification: Ultimovacs ASA
Declaration of Voting Results & Voting Rights Announcements
2020-12-29 English
Shareholder Notification: Ultimovacs ASA
Major Shareholding Notification
2020-12-29 English
Ultimovacs ASA - Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
Regulatory Filings
2020-12-22 English
Ultimovacs ASA - Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma
Earnings Release Q4 2020
2020-12-10 English
Ultimovacs ASA - Announces the Appointment of Ton Berkien as Chief Business Officer
Board/Management Information
2020-11-24 English
Ultimovacs ASA: Third quarter 2020 result presentation
Interim / Quarterly Report Q3 2020
2020-11-12 English
Ultimovacs ASA: Third quarter 2020 result presentation
Investor Presentation
2020-11-12 English
Ultimovacs ASA: Third quarter 2020 result presentation
Earnings Release Q3 2020
2020-11-12 English
Ultimovacs ASA – Extraordinary General Meeting held on 11 November 2020
AGM Information
2020-11-11 Norwegian
Ultimovacs ASA – Extraordinary General Meeting held on 11 November 2020
AGM Information
2020-11-11 Norwegian
Ultimovacs ASA – Extraordinary General Meeting held on 11 November 2020
AGM Information
2020-11-11 Norwegian
Ultimovacs ASA: Invitation to third quarter 2020 results webcast presentation
Report Publication Announcement
2020-11-09 English
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements
2020-11-03 English
Ultimovacs announces Acceptance of Publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer
Regulatory Filings
2020-11-02 English
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 - proposed changes to the Board of Directors
Board/Management Information
2020-10-21 English
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 - proposed changes to the Board of Directors
Proxy Solicitation & Information Statement
2020-10-21 Norwegian
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 - proposed changes to the Board of Directors
AGM Information
2020-10-21 Norwegian
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 - proposed changes to the Board of Directors
Proxy Solicitation & Information Statement
2020-10-21 English
Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer
Legal Proceedings Report
2020-10-19 English
Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
Regulatory Filings
2020-09-30 English
Ultimovacs ASA: Second quarter 2020 result presentation
Interim / Quarterly Report Q2 2020
2020-08-21 English
Ultimovacs ASA: Second quarter 2020 result presentation
Investor Presentation
2020-08-21 English
Ultimovacs ASA: Second quarter 2020 result presentation
Report Publication Announcement
2020-08-21 English
Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma
Regulatory Filings
2020-08-18 English
Ultimovacs ASA: Invitation to second quarter 2020 results webcast presentation
Report Publication Announcement
2020-08-13 English
Ultimovacs ASA Announces First Patient Dosed in the Phase II INITIUM Trial in Metastatic Malignant Melanoma
Regulatory Filings
2020-06-15 English
Ultimovacs ASA Announces First Patient Enrolled in the NIPU Phase II Clinical Trial Testing UV1 Against Mesothelioma
Regulatory Filings
2020-06-15 English
Ultimovacs ASA – New share capital registered
Share Issue/Capital Change
2020-06-05 English
Ultimovacs ASA - Private placement of new shares successfully placed
Share Issue/Capital Change
2020-05-27 English
Ultimovacs ASA - Contemplated private placement
Capital/Financing Update
2020-05-27 English
Ultimovacs ASA Announces Collaboration with Big Pharma Company and Leading European Oncology Clinical Trial Group to Evaluate UV1 in a Third Phase II Clinical Trial
Capital/Financing Update
2020-05-27 English
Ultimovacs ASA - Share Option Program
Share Issue/Capital Change
2020-05-25 English
Ultimovacs ASA: First quarter 2020 result presentation
Interim / Quarterly Report Q1 2020
2020-05-14 English
Ultimovacs ASA: First quarter 2020 result presentation
Investor Presentation
2020-05-14 English
Ultimovacs ASA: First quarter 2020 result presentation
Report Publication Announcement
2020-05-14 English
Ultimovacs ASA: Invitation to first quarter 2020 result webcast presentation
Report Publication Announcement
2020-05-06 English
Ultimovacs ASA – Annual General Meeting held on 23 April 2020
AGM Information
2020-04-23 Norwegian
Ultimovacs ASA – Annual General Meeting held on 23 April 2020
AGM Information
2020-04-23 English
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements
2020-04-14 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
Board/Management Information
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
Remuneration Information
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
Annual Report FY 2019
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
AGM Information
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
AGM Information
2020-04-02 English
Ultimovacs ASA – Notice of Annual General Meeting on 23 April 2020
AGM Information
2020-04-02 English
Ultimovacs ASA – Annual Report 2019
Annual Report FY 2019
2020-04-01 English
Ultimovacs ASA – Annual Report 2019
Report Publication Announcement
2020-04-01 English
Ultimovacs ASA – Possible implications of the coronavirus (COVID-19) pandemic
Regulatory Filings
2020-03-20 English
Ultimovacs ASA: Fourth quarter 2019 result presentation
Interim / Quarterly Report Q4 2019
2020-02-14 English
Ultimovacs ASA: Fourth quarter 2019 result presentation
Investor Presentation
2020-02-14 English
Ultimovacs ASA: Fourth quarter 2019 result presentation
Report Publication Announcement
2020-02-14 English
Ultimovacs ASA – Ultimovacs appoints Carlos de Sousa as new Chief Executive Officer
Board/Management Information
2020-02-13 English
Ultimovacs ASA – Long term results from UV1 clinical study in patients with malignant melanoma
Regulatory Filings
2020-02-07 English
Ultimovacs ASA: Invitation to fourth quarter 2019 result presentation
Report Publication Announcement
2020-02-06 English
Financial calendar
Report Publication Announcement
2020-01-07 English